CollPlant Biotechnologies Ltd. OPHI

OPHI Company Overview

CollPlant Biotechnologies Ltd. is an Israel-based regenerative and aesthetics medicine company focused on the development and commercialization of recombinant human collagen (rhCollagen) produced through genetically engineered tobacco plants. The company operates primarily in the biotechnology, tissue engineering, medical aesthetics, and regenerative medicine industries. Its core technology platform is designed to produce human collagen without animal-derived materials, supporting applications in tissue repair, wound care, organ manufacturing, and injectable aesthetics. Revenue has historically been generated through product sales, licensing agreements, research collaborations, and development partnerships tied to its proprietary collagen technology.

The company’s principal business lines include bioinks for 3D bioprinting, regenerative tissue scaffolds, dermal and soft tissue fillers, and collagen-based medical products. CollPlant has positioned itself as a differentiated player through its plant-derived recombinant collagen platform, which is intended to offer advantages related to biocompatibility, scalability, and reduced risk of zoonotic contamination compared with animal-sourced collagen. Founded in 2004 and headquartered in Rehovot, Israel, the company evolved from agricultural biotechnology research into a specialized regenerative medicine enterprise, later expanding into 3D bioprinting and aesthetics partnerships with global medical technology companies.